Genentech/OSI Tarceva Shows Two-Month Improvement Over Placebo

A placebo-controlled, Phase III study presented at ASCO found a survival benefit in Tarceva patients with refractory non-small cell lung cancer. The rolling NDA is expected to be completed this summer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet